<DOC>
	<DOCNO>NCT02855450</DOCNO>
	<brief_summary>An 8 Week phase Ib , monocentric , randomize , double-masked , vehicle control , parallel group , study 24 Week follow-up period evaluate safety potential efficacy 180 Î¼g/ml recombinant human nerve growth factor ( rhNGF ) eye drop solution versus vehicle patient glaucoma .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy rhNGF Eye Drops Solution Versus Vehicle Patients With Glaucoma</brief_title>
	<detailed_description>This mask , randomize , single-dose , monocentric trial 60 study participant chronic primary open angle glaucoma . Participants may qualify either progressive optic neuropathy despite maximal current therapy ( i.e . IOP reduction ) , stabilize IOP diminished vision ( central peripheral ) . Participants qualify eye randomize 2:1 topical recombinant human nerve growth factor ( rhNGF ) therapy vehicle placebo control . Examinations safety efficacy occur one week follow initiation therapy , 4 , 8 , 12 32 week . All participant either arm follow clinically 4 week cessation therapy .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1 . Patients 18 year age old . Participant must understand sign inform consent . If participant 's vision impair point he/she read informed consent document , document read participant entirety . 2 . Participant 's clinical diagnosis must consistent glaucoma characterize follow feature : ) clinical evidence progressive RGC dysfunction degeneration use visual field and/or structural modality . There must least 3 reliable visual field within 14 month prior enter study ; b ) residual visual field preservation least 1 quadrant . 3 . Participant must medically able undergo testing require flowsheet exam procedure . 4 . Females childbearing potential must agree use effective form birth control . 1 . Participant another optic nerve retinal degenerative disease comorbidity cause significant vision loss , irrespective whether currently treat untreated , could limit possibility visual recovery . 2 . Participant blind one eye . 3 . Participant requirement acyclovir and/or relate product study duration . 4 Participant evidence corneal opacification lack optical clarity . 4 . Participant evidence corneal opacification lack optical clarity . 5 . Participant undergone lens removal last 3 month , without intraocular lens implantation , undergone intraocular lens replacement within 3 month , undergone ocular surgery within 9 month prior initiation study drug . 6 . Participant receive systemic steroid immunosuppressive medication . 7 . Participant currently participate within last 3 month participate clinical trial nonclinically approve drug ocular systemic administration . 8 . Participant uveitis ocular inflammatory disease . 9 . Participant diabetic macular edema . 10 . Participant history ocular herpes zoster . 11 . Participant chemotherapy . 12 . Participant history malignancy , count basal cell carcinoma , UNLESS treat successfully 2 year prior inclusion trial . 13 . Known hypersensitivity one component study procedural medication . 14 . History drug , medication alcohol abuse addiction . 15 . Females childbearing potential ( surgically sterilize post menopausal least 1 year ) exclude participation study meet one follow condition : 1. currently pregnant , 2. positive result urine pregnancy test Screening/Baseline Visit , 3. intend become pregnant study treatment period , 4. breastfeeding , 5. willing use highly effective birth control measure , : Hormonal contraceptive oral , implanted , transdermal , injected and/or mechanical barrier method spermicide conjunction barrier condom diaphragm IUD entire course 30 day study treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>